
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's revised 2025 earnings per share (EPS) estimate has been increased to $17.06, reflecting positive second-quarter results and updated guidance, which indicates strong financial performance. Anticipated year-over-year earnings growth for 2027 is expected due to the implementation of margin initiatives, despite stable assumptions regarding Stars program bonus payments. Furthermore, Humana's superior Medicare Advantage star rating enhances its competitive position in the evolving regulatory landscape, reflecting a solid foundation for future growth.
Bears say
Humana's management anticipates a slight decline in earnings per share (EPS) for 2026 compared to 2025 due to ongoing pressures related to Star ratings, despite margin improvement efforts. Key downside risks include heightened competition in Medicare Advantage, insufficient reimbursement rates, decreasing membership in prescription drug plans, lower Star ratings, and sluggish growth in healthcare services, all contributing to a challenging outlook. Furthermore, the firm's projections suggest a potential 10% shortfall in 2027 EPS estimates, driven by increased investments necessary for Star rating recovery efforts.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares